Table 3.

Effects of Psyfit, completers-only analysis.

Measures		Psyfita			Control groupb			Linear regression analysis
		Mean	SD	d	Mean	SD	d	Beta	t (df)	P value	∆d
MHC-SF
	Baseline	3.52	0.63		3.51	0.63
	2-month	3.95	0.81	0.59	3.81	0.85	0.40	0.08	1.50 (211)	.14	0.19
	Baseline	3.51	0.61		3.50	0.64
	6-month	3.89	0.84	0.52	3.91	0.76	0.58	–0.20	–0.32 (195)	.75	–0.06
WHO-5
	Baseline	11.27	4.45		11.45	4.32
	2-month	12.98	5.11	0.36	11.97	4.78	0.11	0.11	1.98 (211)	.049	0.25
	Baseline	11.07	4.37		11.58	4.45
	6-month	12.72	5.44	0.33	12.59	4.84	0.22	0.04	0.57 (195)	.57	0.11
CES-D
	Baseline	16.57	4.12		16.55	4.18
	2-month	13.35	7.97	0.51	15.58	8.11	0.16	–0.14	–2.12 (211)	.04	0.35
	Baseline	17.04	4.14		16.66	4.00
	6-month	13.35	8.64	0.54	14.87	8.04	0.28	–0.10	–1.50 (195)	.14	0.26
HADS-A
	Baseline	6.27	2.83		6.52	3.03
	2-month	5.49	3.18	0.26	6.68	3.24	–0.05	–0.16	–2.89 (211)	.004	0.31
	Baseline	6.28	2.78		6.57	2.95
	6-month	5.55	3.78	0.22	6.69	3.23	–0.04	–0.14	–2.24 (195)	.03	0.26
MOS SF health
	Baseline	18.66	3.50		17.97	3.66
	2-month	19.40	3.31	0.22	18.09	3.61	0.03	0.11	2.59 (211)	.01	0.19
	Baseline	18.39	3.40		18.39	3.35
	6-month	18.57	3.58	0.05	18.61	3.36	0.07	–0.01	–0.11 (195)	.91	–0.02
MOS SF vitality
	Baseline	14.67	3.17		14.66	2.82
	2-month	15.80	3.39	0.34	15.09	2.86	0.15	0.11	1.88 (211)	.06	0.19
	Baseline	14.37	3.29		14.80	2.83
	6-month	15.53	3.99	0.32	15.39	3.15	0.20	0.048	0.74 (195)	.46	0.12

^a2-month follow-up: n=95, 6-month follow-up: n=89.

^b2-month follow-up: n=119, 6-month follow-up: n=109.